(Q37794160)

23 August 2017

title

Anticancer properties of zoledronic acid (English)

1 reference

23 August 2017

Anticancer Properties of Zoledronic Acid (English)

1 reference

https://api.crossref.org/works/10.3109/07357907.2010.512598

22 July 2024

author name string

Jonathan Green

1

1 reference

23 August 2017

Allan Lipton

2

1 reference

23 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20879838

22 July 2024

publication date

1 November 2010

1 reference

full work available at URL

23 August 2017

http://www.tandfonline.com/doi/pdf/10.3109/07357907.2010.512598

1 reference

https://api.crossref.org/works/10.3109/07357907.2010.512598

22 July 2024

1 reference

23 August 2017

volume

28

1 reference

23 August 2017

issue

9

1 reference

23 August 2017

page(s)

944-957

1 reference

Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Zoledronic acid is effective against experimental malignant pleural effusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Bisphosphonate zoledronic acid enhances the inhibitory effects of gefitinib on EGFR-mutated non-small cell lung carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Metastasis to bone: causes, consequences and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Development and validation of a highly sensitive RIA for zoledronic acid, a new potent heterocyclic bisphosphonate, in human serum, plasma and urine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Biodistribution and plasma protein binding of zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Exploring the anti-tumour activity of bisphosphonates in early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Gamma delta T cells and dendritic cells: close partners and biological adjuvants for new therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Identification of secondary targets of N-containing bisphosphonates in mammalian cells via parallel competition analysis of the barcoded yeast deletion collection.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Bisphosphonates induce breast cancer cell death in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Bisphosphonates induce apoptosis in human breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Differential effects of bisphosphonates on breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Role of tumor-associated macrophages in tumor progression and invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Activation of γδ T cells by bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Zoledronic acid - a multiplicity of anti-cancer action

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Modulation of innate immunity by IL-18.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Decreased response to paclitaxel versus docetaxel in HER-2/neu transfected human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Zoledronic acid-induced regression of multiple metastases at nonskeletal sites

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Regression of melanoma metastases following treatment with the n-bisphosphonate zoledronate and localised radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Zoledronate-induced remission of acute panmyelosis with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.512598

Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma

21 January 2018

22

1 reference

https://api.crossref.org/works/10.3109/07357907.2010.512598

Bisphosphonates in cancer therapy

22 July 2024

36

1 reference

https://api.crossref.org/works/10.3109/07357907.2010.512598

22 July 2024

81

Eidtmann H.

2010

1 reference

https://api.crossref.org/works/10.3109/07357907.2010.512598

22 July 2024

83

19

viii78

Frassoldati A.

2008

1 reference

https://api.crossref.org/works/10.3109/07357907.2010.512598

22 July 2024

Identifiers

1 reference

23 August 2017

1 reference